Ask about this productRelated genes to: CD1a antibody
- Gene:
- CD1A NIH gene
- Name:
- CD1a molecule
- Previous symbol:
- CD1
- Synonyms:
- -
- Chromosome:
- 1q23.1
- Locus Type:
- gene with protein product
- Date approved:
- 1988-05-11
- Date modifiied:
- 2017-07-07
Related products to: CD1a antibody
Related articles to: CD1a antibody
- Unexplained recurrent miscarriage (uRM) is associated with immune dysregulation at the maternal-fetal interface, where dendritic cell (DC) maturation imbalance may play vital roles. This study investigates how prostaglandin E2 receptor EP4 affects DC metabolic reprogramming and maturation, thus regulating immune tolerance in uRM. Immunohistochemistry revealed increased mature DCs (CD86/CD80) and decreased immature DCs (CD1a) in uRM decidua versus healthy controls. Double immunofluorescence demonstrated lower EP4 expression in mature DCs than immature DCs. In vitro, EP4 inhibition promoted monocyte-derived DC maturation (upregulated CD86/CD80) and pro-inflammatory cytokine secretion (TNF-α, IL-6, IL-12), while EP4 activation suppressed these effects. Seahorse analysis showed EP4 blockade enhanced glycolysis via upregulating HK2/PKM2, whereas EP4 activation maintained oxidative metabolism. Mechanistically, EP4 knockdown in DCs suppressed PI3K-AKT-mTOR signaling. These findings suggest that EP4 may be involved in DC maturation through modulation of glycolytic metabolism and PI3K-AKT-mTOR signaling in uRM, while EP4 agonism preserves DC immaturity and metabolic quiescence, suggesting EP4 as a potential therapeutic target for restoring maternal-fetal immune homeostasis in uRM. - Source: PubMed
Publication date: 2026/06/08
Peng LinLiu ChangYe YaoJeschke UdoTang Xinyi - We present two fatal cases of Erdheim-Chester disease (ECD) with unusual presentations: one featuring predominant gastrointestinal involvement with steatorrhea, nodular gastroduodenitis, and extensive visceral infiltration, and another with constrictive pericarditis and pachypleuritis. Both cases displayed characteristic imaging findings including the "hairy kidney" sign, "coated aorta" sign, symmetric long bone osteosclerosis, and diffuse FDG-PET avidity in bone marrow and serosal surfaces. Histopathology confirmed xanthogranulomatous infiltration with foamy histiocytes and Touton giant cells, with immunohistochemistry showing CD68-positive, CD163-positive, CD1a-negative, and S100-negative cells lacking Birbeck granules, consistent with non-Langerhans cell histiocytosis. These atypical organ manifestations, when accompanied by characteristic radiological signs, should prompt consideration of ECD in the differential diagnosis of multisystem inflammatory disorders. - Source: PubMed
Publication date: 2026/05/26
Daniel Andres Ribero-VargasÁlvarez Payares José CJuliana Murillo-Pérez - Langerhans cell histiocytosis (LCH) is a rare clonal proliferative disorder characterized by the accumulation of Langerhans-type dendritic cells in various tissues, including the lungs and skin [1]. One of the major challenges in this disease is its early diagnosis, the most important reason being that pulmonary involvement is rare in this disease. [2]. - Source: PubMed
Publication date: 2026/04/02
Khazaei NargesShirzadi RuhollahMirlohi Seyed Hossein - Juvenile xanthogranuloma (XGJ) is a generally benign non-Langerhans cell histiocytosis (non-LCH) that primarily affects infants and children. It typically presents as a single skin lesion. Disseminated and profuse forms remain rare and can pose diagnostic or therapeutic challenges. The classification of histiocytoses has recently evolved, incorporating disseminated XGJ into group "C" of non-LCH cutaneous histiocytoses. While the prognosis for isolated cutaneous forms is excellent, vigilance regarding potential associations (type 1 neurofibromatosis and juvenile myelomonocytic leukemia) and systemic complications remains essential. We report the case of a four-month-old infant presenting with a purely cutaneous disseminated form of XGJ, confirmed by histopathology and immunohistochemistry, which required systemic corticosteroid therapy due to the rapid spread of the lesions. This study involves a four-month-old infant with no significant family history who has been presenting with gradually progressive papular skin lesions for one month. Clinical examination revealed multiple umbilicated, yellowish-brown papulonodules scattered across the face, trunk, limbs, skin folds, genital mucosa, and scalp; a café-au-lait spot was detected on one limb. Dermoscopy revealed a characteristic "sunset" pattern. Histopathological and immunohistochemical analysis (CD68+, CD163+, CD1a-, CD34-, S100-) confirmed the diagnosis. The staging evaluation revealed no abnormalities. After three months of simple monitoring, the extensive spread of the lesions prompted the initiation of oral corticosteroid therapy (1 mg/kg/day), resulting in partial regression at six weeks. Disseminated XGJ in infants remains a rare condition. Although the course is most often self-limiting, justifying an initial conservative approach, certain extensive forms may require systemic treatment. The dermatologist plays a central role in diagnosis, based on a combination of clinical, dermoscopic, histopathological, and immunohistochemical findings, and in the multidisciplinary decision-making regarding treatment. - Source: PubMed
Publication date: 2026/04/30
Okouango Emelie SimoneBaghad BouchraRachadi HananeChiheb Soumiya - This study applied a suite of human-relevant, non-animal cell models to investigate early events associated with respiratory sensitization induced by 4,4'-methylene diphenyl diisocyanate (MDI), a representative low-molecular-weight respiratory sensitizer. Phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 macrophage-like cells (THP-1M) and primary human monocyte-derived macrophages were exposed to MDI (3-300 µM, 4 h), resulting in a restricted cytokine response characterized primarily by enhanced IL-1α and IL-1β production. In contrast, lipopolysaccharide (LPS, 1 ng/mL-10 µg/mL) induced a pronounced pro-inflammatory response consistent with classical M1-like activation. Flow cytometric analysis of THP-1M indicated a partial M2a-like immunomodulatory phenotype following MDI exposure, characterized by increased CD1a and reduced CD14 expression. This response was accompanied by changes in selected central carbon metabolites, whereas LPS induced changes more consistent with M1-like activation. In human alveolar epithelial type I-like cells (hAELVi), MDI induced changes in selected central carbon metabolites, indicating epithelial metabolic responsiveness. In epithelial-macrophage coculture (hAELVi/THP-1M), metabolic responses to MDI were attenuated while chemokine production (CCL2, CCL5, CXCL8) was enhanced, suggesting macrophage-mediated modulation of epithelial responses and immune cell recruitment potential. In an air-liquid interface coculture model, these early responses were associated with dendritic cell-like activation of THP-1 cells, marked by OX40L upregulation, indicating Th2-skewing potential. Overall, the findings support interacting epithelial-immune key events relevant to respiratory sensitization and highlight the value of incorporating epithelial-immune interactions into new approach methods (NAMs) based hazard assessment. SHORT SUMMARY: 4,4'-Methylene diphenyl diisocyanate (MDI) induced epithelial metabolic changes in vitro and promoted a partial M2a-like immunomodulatory macrophage response associated with alterations in central carbon metabolites. In epithelial-macrophage co-culture, macrophages attenuated metabolic responses while enhancing chemokine production, suggesting modulation of epithelial responses and immune cell recruitment potential. In an air-liquid interface co-culture model, these early events were associated with dendritic cell-like activation of THP-1 cells, marked by OX40L upregulation and indicative of Th2-skewing potential. Together, the findings support interacting key events relevant to proposed adverse outcome pathway concepts for respiratory sensitization and highlight candidate biomarkers and mechanistically relevant cellular responses that may support human-relevant NAM development for low-molecular-weight respiratory sensitizers. - Source: PubMed
Publication date: 2026/05/26
Blömeke BrunhildeLichter JuttaWeßendorf AnnaLobes NatalieJax MelinaAruna OsmondRolle-Kampczyk UlrikeEngelmann BeatriceBergen Martin vonBock Udo